Holen Sie sich die Stockscreener-App
3.51
3.31%
-0.12
Schlusskurs vom Vortag:
$3.63
Offen:
$3.63
24-Stunden-Volumen:
15,820
Relative Volume:
0.48
Marktkapitalisierung:
$41.12M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-10.46%
1M Leistung:
-1.13%
6M Leistung:
+51.29%
1J Leistung:
-54.71%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$3.44
$4.03
52-Wochen-Spanne:
$1.98
$9.50
Nasus Pharma Ltd. Stock (NSRX) Company Profile
Compare NSRX vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NSRX
Nasus Pharma Ltd.
|
3.51 | 41.12M | 0 | 0 | 0 | 0.00 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Nasus Pharma Ltd. Aktie (NSRX) Neueste Nachrichten
At the October 8 meeting, Nasus Pharma (NSRX) shareholders approved all agenda items except one. - Stock Titan
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com South Africa
Nasus Pharma stock reiterated at Market Outperform by Citizens - Investing.com
Nasus Pharma enrolls first patient in NS003 phase 1 trial - Investing.com
Nasus Pharma Enrolls First Patient in Phase 1 PK Trial of NS003 Intranasal Ondansetron for CINV and PONV - Quiver Quantitative
Nasus Pharma Announces Enrollment and Dosing of First - GlobeNewswire
Nasus Pharma CFO Eyal Rubin Resigns, Files Ownership Disclosure - kalkinemedia.com
Rubin Eyal ceases as CFO at Nasus Pharma (NSRX) - Stock Titan
New Nasus Pharma (NYSE: NSRX) share plan could dilute holders while funding anaphylaxis drug trials - Stock Titan
Nasus Pharma (NSRX) taps BTIG to sell new shares for drug trials - Stock Titan
FDA clears nasal epinephrine study for Nasus Pharma (NSRX) targeting anaphylaxis - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - GlobeNewswire
Nasus Pharma Ltd SEC Filing (Sep 14, 2026) - Stock Titan
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis - Yahoo Finance
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Nasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
A company developing nasal allergy medicine will present in New York - Stock Titan
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan
Nasus Pharma (NYSE: NSRX) sets $50M share shelf for working capital and drug development - Stock Titan
Nasus Pharma Announces Transition of Chief Financial Officer - Yahoo Finance
Nasus Pharma (NSRX) CFO exit ushers in long-time insider as interim - Stock Titan
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update - GlobeNewswire
Nasus Pharma Appoints Pharmaceutical Industry Veteran - GlobeNewswire
Nasus Pharma (NYSE American: NSRX) taps Brendan O’Grady to lead next phase - Stock Titan
A new CEO takes charge as Nasus Pharma advances nasal anaphylaxis treatment - Stock Titan
NSRX Forecast — Price Target — Prediction for 2027 - TradingView
Nasus Pharma Announces Positive Results from Preclinical - GlobeNewswire
NSRX - Finviz
Nasus Pharma to Participate in Upcoming Investor Conferences - Yahoo Finance
NSRX: Nasus Pharma Ltd. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasus Pharma Advances NS002 Towards Pivotal Study Following - GlobeNewswire
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - Yahoo Finance
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - GlobeNewswire
Nasus Pharma to Present Topline Analysis from NS002 - GlobeNewswire
Nasus Pharma Announces Pricing of $15.0 Million Private Placement - GlobeNewswire
Finanzdaten der Nasus Pharma Ltd.-Aktie (NSRX)
Es liegen keine Finanzdaten für Nasus Pharma Ltd. (NSRX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Nasus Pharma Ltd.-Aktie (NSRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Teleman Dan Benjamin | Chief Executive Officer |
Apr 22 '26 |
Buy |
3.76 |
2,900 |
10,904 |
156,991 |
| Teleman Dan Benjamin | Chief Executive Officer |
Mar 31 '26 |
Buy |
2.04 |
15,000 |
30,600 |
21,246 |
6.05%
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):